Biodegradable donepezil lipospheres for depot injection: Optimization and in-vivo evaluation

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 10, 2012, Pages 1425-1437

  Yehia, Soad A ^a   Elshafeey, Ahmed H ^a   Elsayed, Ibrahim ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Alzheimer's disease; depot injection; donepezil; glyceryl tripalmitate; lipospheres

Indexed keywords

DONEPEZIL; DRUG CARRIER; GLYCEROL BEHENATE; HEXADECANOL; LIPOSPHERE; TRIPALMITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIODEGRADATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPOT INJECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG ENCAPSULATION EFFICIENCY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TO LIPID RATIO; GAMMA IRRADIATION; IN VITRO STUDY; IN VIVO STUDY; LIPID ANALYSIS; LIPOSPHERE YIELD; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHARMACEUTICS; PLASMA CONCENTRATION-TIME CURVE; RABBIT; SCANNING ELECTRON MICROSCOPY; SYRINGEABILITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CHROMATOGRAPHY, LIQUID; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; INDANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LIPIDS; MALE; MICROSPHERES; NOOTROPIC AGENTS; PARTICLE SIZE; PIPERIDINES; RABBITS; TANDEM MASS SPECTROMETRY; TIME FACTORS; TRIGLYCERIDES;

EID: 84865864627     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01530.x     Document Type: Article

References (47)

1. George T, Grossberg M,. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res 2003; 64: 216-235.
2. Lau L-F, Brodney MA,. Therapeutic approaches for the treatment of Alzheimer's disease: an overview. In:, Lau L-F, Brodney MA, eds. Alzheimer's Disease. New York: Springer, 2007: 1-24.
3. Schonheit B, et al,. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 2004; 25: 697-711. (Pubitemid 38698241)
4. Fleisher AS, et al,. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007; 68: 1588-1595. (Pubitemid 46717983)
5. Larson EB, et al,. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501-509.
6. Geldmacher DS,. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert Rev Neurother 2004; 4: 5-16. (Pubitemid 38082118)
7. Doody RS, et al,. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166. (Pubitemid 32405709)
8. Clark CM, Karlawish JH,. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003; 138: 400-410. (Pubitemid 36262651)
9. Scott LJ, Goa KL,. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-1122.
10. Alva G, Cummings JL,. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) 2008; 5: 27-36.
11. Arlt S, et al,. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging 2008; 25: 1033-1047.
12. Pushpangadan M, Feely M,. Once a day is best: evidence or assumption? The relationship between compliance and dosage frequency in older people. Drugs Aging 1998; 13: 223-227. (Pubitemid 28461782)
13. Small G, Dubois B,. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-2713. (Pubitemid 350146408)
14. Ryan AA,. Medication compliance and older people: a review of the literature. Int J Nurs Stud 1999; 36: 153-162.
15. Cummings J, et al,. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69 (4 Suppl. 1): S10-S13. (Pubitemid 47205654)
16. Grossberg J,. Cholinesterase inhibitors. In:, Lau L-F, Brodney MA, eds. Alzheimer's Disease. New York: Springer, 2007: 25-52.
17. Black SE, et al,. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-469. (Pubitemid 47450281)
18. Yardley J,. Comparison of 23 mg donepezil sustained release (SR) to 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease. ClinicalTrials.gov [Online] 2010. http://clinicaltrials. gov/ct2/show/NCT00478205 (Accessed May 12 2011).
19. Seltzer B,. Donepezil: an update. Expert Opin Pharmacother 2007; 8: 1011-1023. (Pubitemid 351232608)
20. Zhang P, et al,. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007; 28: 1882-1888. (Pubitemid 46123551)
21. Esposito E, et al,. Production of lipospheres for bioactive compound delivery. In:, Nastruzzi C, ed. Lipospheres in Drug Targets and Delivery: Approaches, Methods and Applications. New York, NY: CRC, 2005: 23-40.
22. Nasr M, et al,. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2008; 9: 154-162.
23. Cortesi R, et al,. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002; 23: 2283-2294. (Pubitemid 34234829)
24. Ritger PL, Peppas NA,. A simple equation for description of solute release II. fickian and anomalous release from swellable devices. J Control Release 1987; 5: 37-42. (Pubitemid 17106644)
25. Peppas NA, Sahlin JJ,. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm 1989; 57: 169-172. (Pubitemid 20011841)
26. Lacout J-I, et al,. Method for preparing a calcium phosphate pasty material for injection. U.S. Patent, 6,923,989, 2005.
27. Paul S, et al,. Pressure measurements during injection of corticosteroids. Med Biol Eng Comput 1998; 36: 729-733.
28. Reagan-Shaw S, et al,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661. (Pubitemid 351348146)
29. Apostolou C, et al,. Quantitative determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry employing an automated liquid-liquid extraction based on 96-well format plates. Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 239-244. (Pubitemid 46464046)
30. Shah VP, et al,. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16: 249-255.
31. Jones DS, Pearce KJ,. An investigation of the effects of some process variables on the microencapsulation of propranolol hydrochloride by the solvent evaporation method. Int J Pharm 1995; 118: 199-205.
32. zur Muhlen A, et al,. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-155. (Pubitemid 28167741)
33. Koziara JM, et al,. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99: 259-269. (Pubitemid 39222111)
34. Castellanos Gil E, et al,. Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet. Eur J Pharm Biopharm 2008; 69: 303-311. (Pubitemid 351467173)
35. Paradkar A, et al,. Preparation and characterization of flurbiprofen beads by melt solidification technique. AAPS PharmSciTech 2003; 4: E65.
36. Jelvehgari M, et al,. Effect of formulation and processing variables on the characteristics of tolmetin microspheres prepared by double emulsion solvent diffusion method. Indian J Pharm Sci 2010; 72: 72-78.
37. El-Gibaly I,. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int J Pharm 2002; 249: 7-21. (Pubitemid 35333428)
38. Boelhouwer WM, et al,. Viscosity data of organic liquids. Appl Sci Res 1950; 2: 249-268.
39. Li FQ, et al,. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm 2006; 324: 152-157.
40. Hamdani J, et al,. Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm 2003; 260: 47-57. (Pubitemid 36724860)
41. Koennings S, et al,. Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. J Control Release 2007; 119: 173-181. (Pubitemid 46754503)
42. Liu ZL, et al,. Preparation and characterization of magnetic P(St-co-MAA-co-AM) microspheres. J Magnetism Magn Mater 2006; 302: 529-535.
43. Cherkasov VR, et al,. Synthesis of polymer magnetic microspheres for immunomagnetometric assay. Polym Sci Ser A 2006; 48: 353-358.
44. Clayden J, et al,. Organic Chemistry. New York: Oxford university press, 2001.
45. Boylan JC, Nail SL,. Parenteral products. In:, Florence AT, Siepmann J, eds. Modern Pharmaceutics: Basic Principles and Systems. New York: Informa, 2009: 565-609.
46. Rungseevijitprapa W, Bodmeier R,. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci 2009; 36: 524-531.
47. Smaby N, et al,. Identification of key pinch forces required to complete functional tasks. J Rehabil Res Dev 2004; 41: 215-224.